SiRNA-mediated Downregulation of MMP-9 and UPAR in Combination with Radiation Induces G2/M Cell-cycle Arrest in Medulloblastoma
Overview
Authors
Affiliations
Our previous work and that of other investigators strongly suggest a relationship between the upregulation of metalloproteinase-9 (MMP-9) and urokinase-type plasminogen activator receptor (uPAR) in tumor angiogenesis and metastasis. In this study, we evaluated the role of MMP-9 and uPAR in medulloblastoma cancer cell resistance to ionizing irradiation (IR) and tested the antitumor efficacy of siRNA (short interfering RNA) against MMP-9 [plasmid siRNA vector for MMP-9 (pM)] and uPAR [plasmid vector for uPAR (pU)] either alone or in combination [plasmid siRNA vector for both uPAR and MMP-9 (pUM)]. Cell proliferation (BrdU assay), apoptosis (in situ TUNEL for DNA fragmentation), and cell-cycle (FACS) analyses were carried out to determine the effect of siRNA either alone or in combination with IR on G2/M cell-cycle arrest in medulloblastoma cells. IR upregulated MMP-9 and uPAR expression in medulloblastoma cells; pM, pU, and pUM in combination with IR effectively reduced both MMP-9 and uPAR expression, thereby leading to increased radiosensitivity of medulloblastoma cells. siRNA treatments (pM, pU, and pUM) also promoted IR-induced apoptosis and enhanced IR-induced G2/M arrest during cell-cycle progression. While IR induces G2/M cell-cycle arrest through inhibition of the pCdc2- and cyclin B-regulated signaling pathways involving p53, p21/WAF1, and Chk2 gene expression, siRNA (pM, pU, and pUM) alone or in combination with IR induced G2/M arrest mediated through inhibition of the pCdc2- and cyclin B1-regulated signaling pathways involving Chk1 and Cdc25A gene expression. Taken together, our data suggest that downregulation of MMP-9 and uPAR induces Chk1-mediated G2/M cell-cycle arrest, whereas the disruption caused by IR alone is dependent on p53- and Chk2-mediated G2/M cell-cycle arrest.
Mol Cancer Res. 2021; 19(7):1247.
PMID: 34210818 PMC: 8288031. DOI: 10.1158/1541-7786.MCR-21-0395.
Wang Y, Lin Y, Lin C, Chen Y, Chang C Front Oncol. 2021; 11:646167.
PMID: 33859945 PMC: 8042278. DOI: 10.3389/fonc.2021.646167.
Liang T, Zhang X, Xue W, Zhao S, Zhang X, Pei J Int J Mol Sci. 2014; 15(9):15754-65.
PMID: 25198898 PMC: 4200840. DOI: 10.3390/ijms150915754.
RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.
Luis-Ravelo D, Anton I, Zandueta C, Valencia K, Pajares M, Agorreta J Mol Oncol. 2013; 8(2):196-206.
PMID: 24321314 PMC: 5528549. DOI: 10.1016/j.molonc.2013.11.001.
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Ulasov I, Thaci B, Sarvaiya P, Yi R, Guo D, Auffinger B Cancer Med. 2013; 2(4):457-67.
PMID: 24156018 PMC: 3799280. DOI: 10.1002/cam4.104.